| Literature DB >> 32976702 |
Mario Spaggiari1, Pierpaolo Di Cocco1, Kiara Tulla1, Kerim B Kaylan2, Mario A Masrur3, Chandra Hassan3, Jorge A Alvarez1, Enrico Benedetti1, Ivo Tzvetanov1.
Abstract
Patients with obesity have limited access to kidney transplantation, mainly due to an increased incidence of surgical complications, which could be reduced with selective use of robotic-assisted surgery. This prospective randomized controlled trial compares the safety and efficacy of combining robotic sleeve gastrectomy and robotic-assisted kidney transplant to robotic kidney transplant alone in candidates with class II or III obesity. Twenty candidates were recruited, 11 were randomized to the robotic sleeve gastrectomy and robotic-assisted kidney transplant group and 9 to the robotic kidney transplant group. At 12-month follow-up, change in body mass index was -8.76 ± 1.82 in the robotic sleeve gastrectomy and robotic-assisted kidney transplant group compared to 1.70 ± 2.30 in the robotic kidney transplant group (P = .0041). Estimated glomerular filtration rate, serum creatinine, readmission rates, and graft failure rates up to 12 months were not different between the two groups. Length of surgery was longer in the robotic sleeve gastrectomy and robotic-assisted kidney transplant group (405 minutes vs. 269 minutes, p = .00304) without increase in estimated blood loss (120 ml vs. 117 ml, p = .908) or incidence of surgical complications. Combined robotic-assisted kidney transplant and sleeve gastrectomy is safe and effective compared to robotic-assisted kidney transplant alone.Entities:
Keywords: clinical research / practice; clinical trial; comorbidities; kidney transplantation / nephrology; obesity
Mesh:
Year: 2020 PMID: 32976702 DOI: 10.1111/ajt.16322
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086